• Manuel Sánchez Cánovas, Javier López Robles, Evdochia Adoamnei, Cacho LavinDiegoDMedical Oncology Department, Marques de Valdecilla University Hospital, IDIVAL Research Institute, Santander, Spain., Carmen Diaz Pedroche, Eva Coma Salvans, Teresa Quintanar Verduguez, Francisco José García Verdejo, Mónica Cejuela Solís, Silvia García Adrián, Berta Obispo Portero, Alberto Garrido Fernández, Carmen Salvador Coloma, María Purificación Martínez Del Prado, Jaime Mendiola, and Andres J Muñoz Martín.
• Medical Oncology Department, Morales Meseguer University Hospital, Murcia, Spain. Electronic address: manuelsanchezcanovas@gmail.com.
• Eur. J. Intern. Med. 2024 Aug 20.

AbstractThrombosis may be included in the profile of side effects associated with CDK4/6 inhibitors. Its significance might be greater than reported in randomized clinical trials. To investigate this, a retrospective, multicenter study was conducted. The primary objective was to calculate the incidence of thrombosis associated with CDK4/6 inhibitors. Secondary objectives included examining the impact of thrombosis on survival and identifying predictor variables for the development of venous thromboembolism (VTE) or arterial thrombosis (AT). A total of 986 patients were recruited. The incidence of VTE/AT associated with CDK4/6 inhibitor treatment during the follow-up period was 5.48 %. Survival analysis did not indicate that the development of VTE/AT during CDK4/6 inhibitor treatment significantly impacted patient survival (p = 0.133). In our analysis, two variables were found to be statistically significant (p < 0.05) as predictors of VTE/AT in breast cancer patients receiving CDK4/6 inhibitor therapy. These variables were the presence of central nervous system (CNS) metastasis with an odds ratio (OR) of 3.68 (95 % CI 1.18 - 11.49) and the use of abemaciclib with an OR of 2.3 (95 % CI 1.16 - 4.57).Copyright © 2024. Published by Elsevier B.V.

3 keywords...

hide…